Showing 3281-3290 of 4165 results for "".
- Regeneron to Present New Data and Analyses of High-Dose Aflibercept at ARVO 2023https://modernod.com/news/regeneron-to-present-new-data-and-analyses-of-high-dose-aflibercept-at-arvo-2023/2481537/Regeneron Pharmaceuticals and its collaborator Bayer announced that aflibercept 8 mg and Eylea (aflibercept) Injection will be featured in 18 presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting from April 23-27. Among the presentations wi
- Researchers Explain How Reading Might Contribute to Myopiahttps://modernod.com/news/researchers-explain-how-reading-might-contribute-to-myopia/2481520/Researchers at the State University of New York (SUNY) are publishing a paper explaining how reading might contribute to myopia. In a paper that will be published in the Journal of Vision, scientists demonstrate that the images formed by our eyes during reading lack
- Radius Announces Software Upgrade for Wearable Device for Perimetric Examinationshttps://modernod.com/news/radius-announces-perimeter-software-upgrade-for-wearable-device/2481518/Radius XR has launched its Radius 1.0 software release for perimetric examinations. Its interface is designed to assist eye care practices in delivering more comprehensive glaucoma management. Radius is a portable Vision Diagnostic and Patient Engagement system that combi
- Aviceda Announces 3 Presentations on AVD-104, its Lead Glyco-mimetic Nanoparticle, As Treatment for GA at ARVOhttps://modernod.com/news/aviceda-announces-3-presentations-on-avd-104-its-lead-glyco-mimetic-nanoparticle-as-treatment-for-ga-at-arvo/2481507/Aviceda Therapeutics announced its upcoming oral and poster presentations at the 2023 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in New Orleans, April 23-27, 2023. Detailed results from each of these three studies will be reported at the conference.
- Graybug Announces Name and Trading Symbol Changehttps://modernod.com/news/graybug-announces-name-and-trading-symbol-change/2481478/Graybug Vision announced that it has changed its name to CalciMedica Inc., effective today. In connection with the name change, the company has changed its trading symbol to “CALC.” The company’s common stock will commence trading on March 21, 2023 on the Nasdaq Global
- Kiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meetinghttps://modernod.com/news/kiora-pharmaceuticals-announces-the-acceptance-of-three-abstracts-at-the-2023-arvo-annual-meeting/2481458/Kiora Pharmaceuticals announced three abstract acceptances for oral and poster presentation at the 2023 Association for Research in Vision and Ophthalmology (ARVO) meeting in New Orleans, April 23-27, 2023. Further results from each of these three studies will be reported at the conference.<
- Bruder Healthcare Now Exclusive Licensor of "The Dry Eye Drink"https://modernod.com/news/bruder-healthcare-now-exclusive-licensor-of-the-dry-eye-drink/2481407/Bruder Healthcare, which is part of Hilco Vision, announced an exclusive licensing agreement with Dry Eye Drink LLC, the manufacturer of a portfolio of dry eye products and drink mixes formulated to provide relief for US adults suffering from symptoms of dry eye disease.
- Three-Month Efficacy/Safety Data of SING IMT for AMD Publishedhttps://modernod.com/news/three-month-efficacysafety-data-of-sing-imt-for-amd-published/2481362/The first and largest single-surgeon case series to describe the short-term (3 months) safety and efficacy outcomes of the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT) in patients with severe to profound bilateral central vision impairment due to advanced A
- AcuFocus Announces First Commercial Patients Treated With the IC-8 Apthera IOLhttps://modernod.com/news/acufocus-announces-first-commercial-patients-treated-with-the-ic-8-apthera-iol/2481329/AcuFocus announced that Vance Thompson, MD, of Vance Thompson Vision, Sioux Falls, South Dakota has commercially implanted the first patients with the IC-8 Apthera IOL. The first and only small aperture, non-toric extended depth of focus IOL, the Apthera IOL is FDA approved fo
- Graybug and CalciMedica Enter Into Definitive Merger Agreementhttps://modernod.com/news/graybug-and-calcimedica-enter-into-definitive-merger-agreement/2481257/Graybug Vision and CalciMedica announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on further developing CalciMedica’s lead product candidate Auxora, a proprietary, intr